Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Current Leases (2019 - 2026)

Sunshine Biopharma filings provide 5 years of Current Leases readings, the most recent being $215637.0 for Q4 2025.

  • On a quarterly basis, Current Leases rose 3.79% to $215637.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $215637.0, a 3.79% increase, with the full-year FY2025 number at $215637.0, up 3.79% from a year prior.
  • Current Leases hit $215637.0 in Q4 2025 for Sunshine Biopharma, down from $218053.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $222496.0 in Q2 2025 to a low of $114452.0 in Q2 2024.
  • Median Current Leases over the past 4 years was $122146.0 (2023), compared with a mean of $155924.1.
  • Biggest five-year swings in Current Leases: fell 6.3% in 2024 and later soared 94.4% in 2025.
  • Sunshine Biopharma's Current Leases stood at $123026.0 in 2022, then dropped by 3.54% to $118670.0 in 2023, then soared by 75.07% to $207756.0 in 2024, then rose by 3.79% to $215637.0 in 2025.
  • The last three reported values for Current Leases were $215637.0 (Q4 2025), $218053.0 (Q3 2025), and $222496.0 (Q2 2025) per Business Quant data.